Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Oppenheimer

Oppenheimer upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a market perform rating to an outperform rating in a report released on Tuesday, MarketBeat Ratings reports.

CAPR has been the subject of a number of other research reports. Piper Sandler cut Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price target for the company. in a research report on Thursday, July 30th. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. B. Riley Financial downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a report on Monday, July 27th. Finally, Alliance Global Partners downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Tuesday, July 28th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $29.15.

Capricor Therapeutics Stock Up 7.5%

Shares of NASDAQ:CAPR opened at $10.06 on Tuesday. The company has a market capitalization of $584.89 million, a price-to-earnings ratio of -4.11 and a beta of 0.54. Capricor Therapeutics has a 52 week low of $2.96 and a 52 week high of $40.37. The firm has a 50 day moving average of $14.83 and a 200 day moving average of $24.41.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, sell-side analysts expect that Capricor Therapeutics will post -1.72 EPS for the current year.

Insider Activity

In related news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 25,000 shares of company stock worth $759,158 over the last three months. Company insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its position in Capricor Therapeutics by 2,261.8% during the 2nd quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock worth $36,806,000 after purchasing an additional 1,463,762 shares during the period. Montanova Capital LLC raised its stake in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after buying an additional 274,184 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at about $3,895,000. Glenmede Trust Co. NA lifted its holdings in shares of Capricor Therapeutics by 13.2% in the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock valued at $1,104,000 after buying an additional 4,240 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after buying an additional 361,664 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Oppenheimer upgraded Capricor to Outperform, providing a bullish counterpoint to recent selling pressure and potentially supporting the stock. Capricor Therapeutics Raised to Outperform at Oppenheimer
• Neutral Sentiment: A rejected shareholder vote appears to be pushing Capricor toward a narrower strategic path, potentially reducing available options while management focuses on its remaining programs. The development adds uncertainty but does not by itself establish a change in the company’s clinical outlook. A Rejected Vote Pushes Capricor Toward A Narrower Path
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action against Capricor and certain executives. The complaints allege that company disclosures concerning the Phase 3 HOPE-3 trial failed to disclose changes to the pre-specified statistical analysis plan that lacked FDA agreement; the FDA allegedly viewed resulting analyses as post-hoc and exploratory. Investors who purchased shares during the reported December 17, 2025–July 26, 2026 class period have until September 28, 2026, to seek lead-plaintiff status. These remain allegations, but the litigation creates potential legal costs, reputational damage and additional uncertainty around HOPE-3. CAPR Deadline Securities Class Action
• Negative Sentiment: Investor-rights firms also highlighted Capricor’s recent second-quarter earnings release and conference call, including the absence of a management question-and-answer session with analysts. That unusual communication detail may reinforce concerns about transparency and near-term execution. CAPR Stock Alert Q2 Earnings and Class Action

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.